Eli Lilly: acquisition of an irritable bowel program

(CercleFinance.com) - Organovo Holdings, a US biotechnology company specializing in the development of new treatments for irritable bowel syndrome, announced on Tuesday that the pharmaceutical giant would acquire its lead drug candidate, FXR314.


Under the terms of the agreement, the San Diego, California-based company says it will receive a milestone payment as well as royalties based on the regulatory and commercial progress of the project.

In effect, Lilly will take over all commercialization rights and intellectual property rights to the 'FXR' clinical research program developed by Organovo.

Organovo has made a name for itself by using 3D modeling to evaluate the efficacy of its products under development in human tissue.

Copyright (c) 2025 CercleFinance.com. All rights reserved.